The genomic profile defining IDH1/2-mutant gliomas (e.g., IDH1/2, ATRX, and TP53 mutations) was significantly enriched in younger patients (≤40 years), whereas the profile characteristic of IDH1/2-wild-type GBM (e.g., TERTp mutations, EGFR amplification, PTEN alterations, and chromosome 7+/10−) predominantly occurred in older patients (≥58 years) (Fig. 3A and B). This evidence concerns the gene ATRX and central nervous system cancer.